Avaliação da Resposta Pró-Inflamatória Sistémica Associada à Retinopatia Diabética como Fator Limitante da Eficácia do Tratamento Intravítreo para Edema Macular Diabético

Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35:556-64. doi: 10.2337/dc11-1909.

Kern TS, Engerman RL. A mouse model of diabetic retinopathy. Arch Ophthalmol. 1996; 114:986-90. doi: 10.1001/archopht.1996.01100140194013.

Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54:1615-25. doi: 10.2337/diabetes.54.6.1615.

Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999; 96:10836-41. doi: 10.1073/pnas.96.19.10836.

Rangasamy S, McGuire PG, Franco Nitta C, Monickaraj F, Oruganti SR, Das A. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. PLoS One. 2014; 9:e108508. doi: 10.1371/journal.pone.0108508.

Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996; 103:1820-28. doi: 10.1016/s0161-6420(96)30420-x.

Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010; 117:1078-86;1072. doi: 10.1016/j.ophtha.2010.03.045.

Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013; 120:2013-22. doi: 10.1016/j.ophtha.2013.02.034.

Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID Studies. Ophthalmology 2016; 123:2376-85. doi: 10.1016/j.ophtha.2016.07.032.

Maggio E, Sartore M, Attanasio M, Maraone G, Guerriero M, Polito A, et al. Anti-vascular endothelial growth factor treatment for diabetic macular edema in a real-world clinical setting. Am J Ophthalmol. 2018; 195:209-22. doi: 10.1016/j.ajo.2018.08.004.

Ozturk BT, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis. 2009; 15:1906-14.

Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009; 116:73-9. doi: 10.1016/j.ophtha.2008.09.037.

Brito P, Costa J, Gomes N, Costa S, Correia-Pinto J, Silva R. Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF. J Diabetes Complications. 2018; 32:643-9. doi: 10.1016/j.jdiacomp.2018.05.006.

Brito P, Costa J, Gomes N, Costa S, Correia-Pinto J, Silva R. Serum pro-inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti-VEGF: association with intravitreal injection treatment profiles in real-world setting. Acta Ophthalmol. 2020; 98:e421-e427. doi: 10.1111/aos.14308.

Brito PS, Costa JV, Barbosa-Matos C, Costa SM, Correia-Pinto J, Silva RM. Association of serum vasogenic and proinflammatory factors with clinical response to anti-vascular endothelial growth factor for diabetic macular edema. Retina. 2021; 41:345-54. doi: 10.1097/IAE.0000000000002852.